|
Thursday, October 7, 2010
|
|
Pre-Conference – Cystic Fibrosis
|
|
7:00am-12:30pm
|
Cystic Fibrosis Pre-Conference
|
|
7:00-7:30 am
|
Preconference Breakfast (for preconference participants only)
|
|
7:30-7:35 am
|
Overview and Introduction
Robert Kuhn, PharmD
|
|
7:35-8:05 am
|
CF: Current Challenges and Implications for Drug Therapy
0180-0000-10-034-L01-P
Lisa Lubsch, PharmD
At the completion of this activity, the participant will be able to:
1. Review the pathogenesis of lung disease in cystic fibrosis
2. Discuss the potential and available therapies for management of cystic fibrosis as they relate to the pathogenesis of lung disease
3. Describe the current challenges affecting drug therapy for cystic fibrosis and possible solutions
|
|
8:05-8:40 am
|
Pancreatic Enzymes, Vitamins and the Liver
0180-0000-10-010-L01-P
Kim Novak, PharmD
At the completion of this activity, the participant will be able to:
1. Discuss the current status of vitamin supplementation and monitoring in CF
2. Discuss the current status of pancreatic enzyme therapy in the US
3. Explain the selection of pancreatic enzyme products based on patient and pharmaceutical factors
|
|
8:40-9:15 am
|
Selection of Antibiotics, Dosing and Length of Therapy
0180-0000-10-036-L01-P
Robert Kuhn, PharmD
At the completion of this activity, the participant will be able to:
1. Identify the common respiratory pathogens in CF and possible anti-microbial regimens for treatment.
2. Discuss key pharmacokinetic factors that influence methods of delivery of anti-microbial agents in CF.
3. Identify key endpoints for determining the length of antibiotic therapy in CF
|
|
9:15-9:30 am
|
Break
|
|
9:30-10:15 am
|
How To Do Continuous Infusion Antibiotics: Lessons Learned
0180-0000-10-038-L01-P
Jeff Zobell, PharmD
At the completion of this activity, the participant will be able to:
1. Describe the use of continuous infusion (CI) antibiotics as a possible strategy to manage acute pulmonary exacerbations of CF
2. Restate the rationale for delivering beta-lactams via CI
3. Discuss the literature supporting the use of CI beta-lactams in CF
|
|
10:15-10:50 am
|
Aerosol Drug Therapy in CF; Current Status
0180-0000-10-008-L01-P
Alison Grisso, PharmD
At the completion of this activity, the participant will be able to:
1. Identify key factors influencing drug delivery in a CF patient?s airway
2. Identify correct aerosol delivery systems for current inhaled antibiotics
3. Describe the use of aerosol drug therapy in CF patients including aztreonam, colisthemethate and tobramycin
|
|
10:50-11:30 am
|
Case Reviews; Panel Question and Answer
|
|
11:30am-1:00pm
|
Lunch (for Preconference participants only)
|
|
11:30am-1:00pm
|
New Practitioner Luncheon
|
|
ANNUAL MEETING STARTS NOW!
|
|
1:30-3:00pm
|
Resuscitation and RSI Pharmacotherapy – Level 1 (PICU)
0180-0000-10-001-L04-P
Melissa Hunt, PharmD
Clinical Pharmacy Specialist
Huntsville Hospital for Women and Children
Huntsville, AL
By the end of this presentation, participants will be able to:
-
Review Pharmacology and indications of resuscitation medications
-
Identify indications and steps of RSI
-
Given specific patient cases, be able to determine the most appropriate medications to use during resuscitation of RSI situations.
-
Identify important aspects of medication administration
-
Describe pharmacist benefit during code and RSI situations
|
|
Neonatal Abstinence Syndrome – Level 2 (NICU)
0180-0000-10-002-L04-P
Peter Gal, PharmD
Director, Graduate Pharmacy Education
Greensboro AHEC and Moses Cone Health System
Greensboro, NC
By the end of this presentation, participants will be able to:
-
Describe the reasons to initiate a drug screen in baby for possible maternal drug abuse
-
Identify the sites useful for monitoring a drug screen and what do the results represent
-
Review the monitoring/scoring systems for Neonatal Abstinence Syndrome
-
Compare and contrast the treatment strategies for Neonatal Abstinence Syndrome and what are the risks and benefits of each strategy
-
Discuss issues regarding breast feeding for drug abusing mothers
-
Describe appropriate healthcare team strategies for discharge of addicted neonate
|
|
Topics in Pediatric Anticoagulation – General Session
0180-0000-10-003-L04-P
Cyrine Haidar, PharmD
Clinical Pharmacist
St. Jude Children’s Research Hospital
Memphis, TN
By the end of this presentation, participants will be able to:
-
Describe the challenges related to pediatric anticoagulation
-
Explain the steps needed to create guidelines for pediatric anticoagulation
-
Indentify and explain the challenges related to outpatient anticoagulation management in pediatric patients
|
|
3:00-3:15pm
|
Break
|
|
3:15-4:45pm
|
Approach to a Complicated Patient in the Pediatric Clinical Care Unit, Level 1 (PICU)
0180-0000-10-004-L04-P
Kelly Kopec, PharmD
Clinical Pharmacist PICU/Pediatrics, Clinical Assistant Professor
The University of Illinois Medical Center at Chicago
Chicago, IL
By the end of this presentation, participants will be able to:
-
Given a patient case:
-
Calculate the maintenance fluid requirements and disease states or conditions that may alter maintenance fluid requirements.
-
Calculate a creatinine clearance and recognize altered creatinine levels across pediatric age groups
-
Identify drug classes to avoid or alter in renal insufficiency
-
Recognize normal vital signs across pediatric age groups
-
Evaluate patient specific lab data and understand how “normal” or “abnormal” values are affected by a patient’s age and disease state
-
Given a particular age group, identify the most likely pathogens and how the pathogens change for a community vs. a hospital acquired infection for the following disease states: sepsis, meningitis and pneumonia
-
Discuss and identify agents for sedation and appropriate situations for use
|
|
Neonatal Circulatory Support – Level 2 (NICU)
0180-0000-10-005-L04-P
Christopher McPherson, PharmD
Neonatal ICU Clinical Pharmacist
St. Louis Children’s Hospital
St. Louis, MO
By the end of this presentation, participants will be able to:
-
Define hypotension in newborns of different gestational ages
-
Describe the physiologic etiologies of hypotension as a basis for intervention
-
Select medications to improve perfusion in neonates based on etiology
-
Contrast treatment goals in term versus preterm neonates based on the clinical consequences of hypoperfusion
|
|
Management of Pulmonary Hypertension – General Session
0180-0000-10-006-L04-P
Cortney Rogers, PharmD
Clinical Pharmacist
St. Louis Children’s Hospital
St. Louis, MO
By the end of this presentation, participants will be able to:
-
Review the mechanism of action of the medications used to treat pulmonary hypertension as it relates to the pathophysiology of the disease
-
Compare and contrast the medications used in the management of pulmonary hypertension focusing on pharmacokinetics, dosing strategies, drug interactions, adverse effects and product acquisition
-
Identify opportunities for pharmacists to optimize medication therapy management of pediatric patients with pulmonary hypertension
|
|
4:45-5:00pm
|
Break
|
|
5:00-6:00pm
|
Keynote Address
Building a Standardized Approach to Acute Pediatric Care
0180-0000-10-007-L04-P
 James Broselow, MD
Medical Director
Artemis
At the end of this session, participants will be able to:
1) Review the history of why acute pediatric care has been and still is a "bad system"
2) Identify the steps needed to build a standardized approach to acute medication administration in children.
3) Demonstrate how the principals learned have been incorporated into the Artemis Project at PPAG
After graduating from Dartmouth College with honors in economics, Dr. Broselow obtained his medical degree from NJ College of Medicine and Dentistry and entered the field of family practice, in which he became board certified and practiced in Frankenmuth Michigan. He continued on to become board certified in Emergency Medicine. It was while working in the emergency department of a community hospital in Hickory, North Carolina, that he recognized how difficult and stressful it was for him and his team to care for acutely ill or injured children. He has conducted original research concerning the correlation between length and weight in children, from which the “Broselow Tape” was born.
He has worked with Dr. Allen Hinkle on the Broselow-Hinkle organizer and co-developed the Broselow tape and subsequent Broselow-Luten System with Robert Luten, MD . He has recently taken a position on the faculty of the University of Florida so that he can work more closely with Dr. Luten as they continue to develop their pediatric patient safety system. Currently, he is the Medical Director of PPAG's Artemis Safety Initiative.
Through his numerous and significant innovations in pediatric care, the Broselow name has become one of the most widely recognized in the field of emergency medicine.
|
|
6:00-5:30pm
|
PPAG Fellows Awards
|
|
6:30-7:30pm
|
Opening Reception honoring Fellows
|
|
Friday, October 8, 2010
|
|
8:00-9:00am
|
Sumner J. Yaffe Award
Pediatric Pharmacology and Therapeutics
0180-0000-10-037-L04-P
 Michael Reed, PharmD
|
|
9:00-10:00am
|
Best Practice Award Presentation: The impact of a pharmacist-managed RSV Prevention Clinic on palivizumab compliance and RSV associated hospitalization.
0180-0000-10-009-L01-P
Jennifer Chow, PharmD
Children’s Hospital of the King’s Daughter
Norfolk, VA
|
|
10:00-10:15am
|
Break
|
|
10:15-11:45am
|
Research Workshop: Pharmacogenomics Impact on Pediatric Pharmacy Practice
0180-0000-10-012-L04-P
Mary Kennedy, PharmD
Assistant Professor
Virginia Commonwealth University School of Pharmacy
Richmond, VA
By the end of this presentation, participants will be able to:
-
Review basic principles of developmental pharmacogenomics and special considerations for pharmacogenomic testing in children
-
Discuss potential applications and limitations of pharmacogenomic testing in pediatric patients
-
Identify potential roles for the pediatric clinical pharmacist in pharmacogenomics
|
|
Advocacy Workshop: Healthcare Reform
0180-0000-10-013-L04-P
John McGlew, MA
Associate Director, Government Affairs
ACCCP
Washington, DC
By the end of this presentation, participants will be able to:
-
Describe the background to the health care reform debate and the work of the pharmacy profession in anticipation of this process
-
Identify the key provisions in the health care reform law pertaining to pharmacist-delivered patient care
-
List the congressional committees, key members of Congress and regulatory departments and agencies with jurisdiction over the pharmacy provisions identified in (2) Describe the work the pharmacy profession has undertaken to implement these provisions
|
|
Academia Workshop: The Changing Face of the Pediatric Faculty Member – Faculty Panel Discussion
0180-0000-10-014-L04-P
Lea Eiland, PharmD
Associate Clinical Professor and Associate Department Head of Pharmacy Practice, Auburn University
Sherry Luedtke, PharmD
Associate Dean, Professional Affairs, TTUHSC School of Pharmacy
Timothy Todd, PharmD
Associate Professor of Pharmacy Practice, Midwestern University Chicago College of Pharmacy
Rachel Meyers, PharmD
Clinical Assistant Professor, Rutgers University
By the end of this presentation, participants will be able to:
-
Describe the rewards of becoming a faculty member
-
List requirements to obtain a faculty position
-
Identify different types of faculty appointments
-
Define the core responsibilities of an academic position
-
Describe different ways a pediatric pharmacist integrates into an academic practice
|
|
12:00-2:00pm
|
Lunch and Committee Meetings
|
|
2:00-3:00pm
|
Super Session: Fetal Care
0180-0000-035-L04-P
Ed Yang, MD
Co-Director, St. Louis Fetal Care Institute
Assoc. Prof. of Pediatric Surgery
Director of ECMO program
Cardinal Glennon and St. Louis University
St. Louis, MO
At the completion of this activity, the participant will be able to:
1. Understand how a fetal diagnosis and therapy center helps expectant mothers
2. Understand what diagnoses are amenable to fetal surgery
3. Understand what pharmacologic problems are relevant to fetal surgery
|
|
3:15-4:00pm
|
PPAG Special Interest Groups (SIGs) Interest Meeting
|
|
4:30-7:30pm
|
Exhibits and PPAG Celebration
|
|
4:30-7:30pm
|
Onsite Learning: Hospital Visits
(Must be pre-registered to participate)
 Live at St. John’s Mercy Children’s Hospital
0180-000-10-015-L04-P
At the completion of this activity, the participant will be able to:
1. Describe four NICU patient room design factors that affect drug therapy.
2. Describe four uses of technology that support safe and efficient drug use in NICU at SJMCH.
3. List decentralized services provided by pharmacy staff within the Children’s Hospital pharmacy.
4. List three patient related centralized pharmacy services.
5. Describe pharmacy resources for SJMCH-include staff resources and space/equipment.
 Live at Ranken Jordan Children’s Rehabilitation Center
0180-000-10-015-L04-P
At the completion of this activity, the participant will be able to:
1. List eight specific areas of drug therapy in pediatric rehabilitation patients
2. List services provided by pharmacy staff at Ranken Jordan.
3. List three pharmacy services contracted to outside pharmacies
4. Describe pharmacy resources at RJ - include staff resources and space/equipment.
|
|
Saturday, October 9, 2010
|
|
8:00-9:00am
|
Clinical Pearls – Changing Times: Updates from the World of Poisonings
0180-0000-10-016-L04-P
Rebecca Tominack, MD
Assistant Medical Director
Missouris Poison Center of SSM Cardinal Glennon Children’s Medical Center
St. Louis, MO
By the end of this presentation, participants will be able to:
-
Understand why poisoning is considered a pediatric problem
-
Explain the triage process for a pediatric patient with an ingestion, including the important questions to address
-
Describe changes in gastrointestinal decontamination over the last decade
-
Review the most appropriate source of information for pediatric poisonings
|
|
9:00-10:00am
|
Scientific Platform Presentations
Evaluation of Vancomycin Dosing for Complicated Infections in Pediatric Patients
0180-0000-10-018-L04P
Spencer Durham, PharmD
Sacred Heart Children’s Hospital
Pensacola, FL
Validation of a Set of Asthma Illustrations in Children with Chronic Asthma in the Emergency Department
0180-000-10-019-L04-P
Danica Irwin, PharmD
Children’s Hospital Eastern
Ontario, Canada
Argatroban and lepirudin utilization in a pediatric population: a five year experience
0180-0000-10-020-L04-P
Emma Thone, PharmD Candidate
Butler University
Indianapolis, IN
Eicosapentaenoic acid attenuates bile acid-induced apoptosis via the Fas and TRAIL-R2 death receptors in HepG2 cells
0180-0000-10-017-L04P
Emma Tillman, PharmD
The University of Tennessee
Memphis, TN
|
|
10:00am-12:00n
|
Poster Session
|
|
12:00-2:00pm
|
PPAG Town Hall Lunch
|
|
2:00-3:00pm
|
Richard A. Helms Award
Advances in Antimicrobial Therapy in Pediatric Patients with Cystic Fibrosis in the Last 20 years
0180-0000-10-033-L04-P
Robert Kuhn, PharmD
By the end of this presentation, participants will be able to:
-
Identify three key advances in the antimicrobial therapy in patients with CF in the last twenty years
-
List three strategies to improve collegial growth in your career
-
Describe key elements in mentoring of students and residents
|
|
3:00-3:15pm
|
Research Award Presentations
|
|
3:15-3:30pm
|
Break
|
|
3:30-5:00pm
|
A Case Approach to Fluid, Electrolyte, Nutrition Management in a Preemie, Level 1 (NICU)
0180-0000-10-021-L04-P
Rita Chrivia, RD
Neonatal Dietitian
SSM Cardinal Glennon Children’s Medical Center
St. Louis, MO
By the end of this presentation, participants will be able to:
-
Describe appropriate ranges for glucose infusion, grams of protein per kg, and grams of fat per kg for a preterm infant
-
Identify appropriate methods of fortifying human milk for the preterm infant
-
Recommend nutritionally related medication commonly used with the preterm infant
|
|
Dosing in ECMO and CRRT, Level 2 (PICU)
0180-0000-10-022-L04-P
Rita Jew, PharmD
Executive Director, Pharmacy & Clinical Nutrition Services
Orange, CA
Morgan Cole, PharmD
By the end of this presentation, participants will be able to:
-
Discuss factors that affect drug disposition during extracorporeal membrane oxygenation (ECMO)
-
Identify differences in pharmacokinetic and pharmacodynamics of drugs commonly used during ECMO
-
Recommend dosing strategies for drugs commonly used during ECMO
-
Describe differences between convection and diffusion in continuous renal replacement therapies (CRRT)
-
Discuss the variables in CRRT in children
-
Review the theories behind calculating an estimation of medication clearance on CRRT
|
|
Cerebral Palsy, General Session
0180-0000-10-023-L04-P
Mary Worthington, PharmD
Associate Professor of Pharmacy Practice
Samford University
Birmingham, AL
By the end of this presentation, participants will be able to:
-
Discuss treatment of generalized and localized/segmental spasticity associated with cerebral palsy
-
Develop a monitoring plan for a patient with cerebral palsy spasticity
-
Describe strategies for managing pain and osteopenia in patients with cerebral palsy
|
|
5:00-5:15pm
|
Break
|
|
5:15-6:45pm
|
Warning: Pregnant or Nursing Mom, Level 1 NICU
0180-0000-10-024-L04-P
Carla Christensen, PharmD
Assistant Professor, Pharmacy Practice
Creighton University
Omaha, NE
Kay Kyllonen, PharmD
Neonatal ICU Clinical Specialist, Pharmacy Practice Resident Director
Cleveland Clinic
Cleveland, OH
By the end of this presentation, participants will be able to:
-
Describe key concepts of the pharmacodynamic alterations during pregnancy and lactation
-
Recognize the properties which make a medication likely to cross the placenta and reach the breast milk
-
Assess the benefit of maternal treatment versus the risk to the developing fetus or infant
-
Determine strategies for optimizing maternal therapies while minimizing medication exposure to a nursing infant or developing fetus
-
Review the sources of available information on the safety of medications administered while nursing and/or pregnant
|
|
Sepsis and Septic Shock, Level 2 PICU
0180-0000-025-L04-P
Kara Kniska, PharmD
PICU Clinical Specialist
St. Louis Children’s Hospital
St. Louis, MO
By the end of this presentation, participants will be able to:
-
Review the current pediatric septic shock treatment guidelines
-
Compare and contrast the different inotrope and vasopressor options for septic shock in the pediatric patient
-
Discuss the literature for use of corticosteroids in septic shock and how many it may apply to the pediatric patient
-
Describe the use of Drotecogin alfa (activated) in adult septic shock and its use in children
|
|
Pharmacist Development, General Workshop
0180-0000-10-026-L04-P
Melissa Heigham, PharmD, BCOP
Manager, Clinical Pharmacy Services
St. Louis Children’s Hospital
St. Louis, MO
By the end of this presentation, participants will be able to:
-
Explain the importance of a staff development program
-
Describe processes utilized to identify staff development needs
-
Identify learning experience opportunities which facilitate staff development
-
Review residency preceptor qualifications
-
List examples of residency preceptor development activities
|
|
Sunday, October 10, 2010
|
|
8:00-9:00am
|
Pediatric and Neonatal Hot Topics
0180-0000-10-027-L04-P
Kathy Pham, PharmD
National Children’s Medical Center
Washington, DC
By the end of this presentation, participants will be able to:
-
Discuss new basic research finding as they relate pediatric pharmacotherapy during the last year
-
Discuss new clinical finding in pediatric pharmacotherapy that may have impact upon patient care
-
Summarize future directions for advances in the field of pediatric pharmacotherapy
|
|
9:15-10:45am
|
Research Workshop, How To Get Your Residency Research Project Done in One Year, 0180-0000-10-028-L04-P
Emma Tillman, PharmD
Fellow and Instructor, Department of Clinical Pharmacy
University of Tennessee HSC, College of Pharmacy
Memphis, TN
Elizabeth Farrington, PharmD
Clinical Assistant Professor
University of North Carolina
Chapel Hill, NC
Robert Kuhn, PharmD
Professor of Pharmacy Practice and Science
University of Kentucky
Lexington, KY
By the end of this presentation, participants will be able to:
-
Discuss development of project list prior to the start of the residency
-
List the pro’s and con’s of a residency project that required the patient’s informed consent
-
Understand the benefits of weekly, monthly vs. quarterly meetings to the resident’s success
|
|
Advocacy Workshop, Getting Involved in a Child Health Initiatives at the Local and International Levels
0180-0000-10-029-L04-P
Tracy Hagemann, PharmD
Associate Professor
The University of Oklahoma College of Pharmacy
Oklahoma, OK
Brooke Honey, PharmD, BCPS
Assistant Professor
The University of Oklahoma College of Pharmacy
Oklahoma, OK
Peter Johnson, PharmD
Assistant Professor
The University of Oklahoma College of Pharmacy
Oklahoma, OK
By the end of this presentation, participants will be able to:
-
List 3 potential barriers for pharmacists that may affect involvement in pediatric health-initiatives
-
Describe 3 oppportunities in your professional life where you could become involved in pediatric health-initiatives
-
Recognize the unique skills that a pediatric pharmacist can provide in public health-initiatives for children
|
|
Pediatric Electronic Medical Record
0180-0000-10-030-L04-P
Beth Carberry, MBA
By the end of this presentation, participants will be able to:
-
Develop a broad understanding of unique pediatric pharmacy implications associated with the implementation of an electronic medical record
-
Identify common software development gaps and risks associated with a mixed patient environment for the pediatric patient
-
Develop an understanding of pediatric standardization and associated safety implications with pediatric electronic medical record implementation
-
Discuss the unique aspects of the available software for the electronic medical record
|
|
10:45-11:0am
|
Break
|
|
11:00-12:00pm
|
Super Session, Clinical Microbiology Review
0180-0000-10-031-L04-P
David Hunstad, MD
Assistant Professor of Pediatrics and Molecular Microbiology
Washington University School of Medicine
St. Louis, MO
Carey-Ann Burnham, PhD
By the end of this presentation, participants will be able to:
-
Describe 3 methods of antimicrobial susceptibility testing and the criteria for interpretation and reporting results to the provider
-
Discuss therapeutic implications of emerging antibiotic resistance determinants in clinical practice
-
Describe how rapid molecular detection of resistance determinants in clinical samples can optimize empiric antimicrobial therapy
|
E-mail this page to a friend (requires login).